Ignite Creation Date:
2024-05-06 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 2:50 PM
Study NCT ID:
NCT05695976
Status:
RECRUITING
Last Update Posted:
2024-04-17
First Post:
2022-12-20
Brief Title:
GRETeL Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide TMZ to Evaluate Tumor Response Via Liquid Biopsies GRETeL
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma GBM and to determine if plasma circulating tumor DNA ctDNA or cell free DNA cfDNA is associated with disease recurrence survival tumor characteristics andor peripheral immunosuppression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None